About Contact Us Careers

Precision Medicine Market Size and Forecast, by Technology (Bioinformatics, Big Data Analytics, Drug Discovery, Gene Sequencing, Companion Diagnostics); Application (CNS, Immunology, Oncology, Respiratory); End use (Diagnostic Centers, Hospital, Healthcare IT companies) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 6315
  • Published Date: Sep 17, 2025
  • Report Format: PDF, PPT

Precision Medicine Market Outlook:

Precision Medicine Market size was over USD 108.87 billion in 2025 and is anticipated to cross USD 452.07 billion by 2035, growing at more than 15.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of precision medicine is assessed at USD 123.86 billion.

Precision Medicine Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Precision oncology is the largest segment in the drug development pipeline. It has emerged as a potential clinical strategy in oncology to provide the most accurate and optimal treatment to patients based on their genetic profiles. Owing to the genetic diversity and the rapidly evolving dynamics of genomic profiles, treatment efficacy is possible if cancer therapeutics shift from a generalized approach to a tailored treatment strategy. Precision oncology is the most prominent use case of precision medicine and is expected to tackle various obstacles faced in cancer management, including genomic heterogeneity of tumors, unexplained drug resistances, and lack of appropriate methods for monitoring responses to treatments. 

Key Precision Medicine Market Insights Summary:

  • Regional Highlights:

    • The North America precision medicine market is anticipated to capture 45% share by 2035, driven by well-defined regulatory processes and increasing adoption of personalized medicine.
    • The Asia Pacific market will achieve a 30.50% share by 2035, driven by low-cost clinical trials and increasing healthcare investments in countries like India and China.

  • Segment Insights:

    • The hospital segment in the precision medicine market is projected to achieve significant growth till 2035, driven by hospitals' role in personalized care and access to advanced diagnostics and therapeutics.
    • The oncology segment in the precision medicine market is expected to achieve significant share by 2035, driven by increasing global cancer prevalence and advances in precision cancer therapy.

  • Key Growth Trends:

    • Growing investments in R&D activities
    • Groundbreaking developments in biomarker-guided therapies

  • Major Challenges:

    • High cost
    • Impact of turnaround time

  • Key Players: Tepnel Pharma Services, Qiagen, Menarini Silicon Biosystems, Eagle Genomics, Quest Diagnostics, Pfizer, Roche, Biocrates Life Sciences, Teva Pharmaceutical, NanoString Technologies.

Global Precision Medicine Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 108.87 billion
    • 2026 Market Size: USD 123.86 billion
    • Projected Market Size: USD 452.07 billion by 2035
    • Growth Forecasts: 15.3% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (45% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Germany, Japan, United Kingdom
    • Emerging Countries: China, India, Brazil, Mexico, South Korea

    • Last updated on : 17 September, 2025

Growth Drivers

  • Growing investments in R&D activities - Pharma companies and R&D stakeholders have identified the value of pioneering innovative therapies and capitalizing on the commercialization window under patent protection. Consequently, there is a positive correlation between the investment level and the ROI perceived. Furthermore, the maturity, size, and strategy of the company such as the expenditure on clinical trials among pre-clinical companies and on the development of CDx among companies without a CDx program influence the pharma stakeholders.

    Collectively, investments in research tools including genomics, cellomics, proteomics, liquid biopsy, microscopy, and imaging is booming at a rapid rate. Omics-based research tools have enabled pharmaceutical companies to capture a high volume of data per sample, at higher sensitivity and resolution. Among the above mentioned research tool categories, genomics has gained the highest traction, investment, and ROI ratings.

    The success of the Human Genome Project has driven prominent funding in genomic tools over the past few years.

    While still vital parts of the R&D process, the level of funding in cellomics and proteomics is relatively lower than in genomics, due in part to the rising molecular and biological complexity of these analytes compared to nucleic acids. In September 2022, the CDC announced an investment of USD 90.0 million in the Pathogen Genomics Centers of Excellence (PGCoE) network to pilot and implement genomics technologies in the United States public health system.

    Additionally, the WHO in February 2024 announced a funding of USD 4.0 million for a catalytic grant fund catering to organizations working in pathogen genomic surveillance in low- and middle-income countries.
  • Groundbreaking developments in biomarker-guided therapies- Modern medical research is devoted to pioneering personalized pharmacotherapies and understanding molecular phenotypes in diseases. Within this context, biomarkers-guided therapies provide useful information about the molecular etiology, type, and stage of a disease. A biomarker is quantitatively measured and includes a wide array of biological components including DNA, mRNA, microRNA, small interfering RNA, proteoglycans, proteins, lipids, and sphingolipids. These are detectable in samples of blood, tissues, and urine.

    The current landscape of next-generation sequencing (NGS) has promoted the detection of gene alterations, particularly gene mutations, copy number changes, and rearrangements. This has fostered efforts towards precision medicine to render therapies in accordance with genetic alterations. Its proof-of-concept was initiated from the imatinib success for chronic myelogenous leukemia (CML) patients harboring the BCR-ABL translocation. Subsequently, drugs targeting the ALK, EGFR, ROS1, MET-mutant lung cancer, gastric cancer, HER2-overexpression breast cancer, and BRAF V600E mutant melanoma improved patient prognosis and proliferated innovations in precision medicine. 

    The rampant exploration of new drug trial designs has contributed to evaluating and innovating treatments using precision medicine. In February 2024, Mindera Health entered into a partnership with Liviniti to pilot a program using Mind.Px and enhance the clinical outcome of psoriasis.

Challenges

  • High cost- The high expense of precision medicine is attributed to the extensive collection of information required, despite its potential for tailoring therapies to individual needs. Gathering and examining a substantial volume of data is not only expensive but also requires significant labor and technical expertise. Data anonymization and its security are significant concerns thereby, restricting the precision medicine market growth.
  • Impact of turnaround time - The minimum turnaround time for data analysis is 26 hours, which is still considered slow for making choices in acute care settings. Calculating the validity of such data is equally challenging. Rapid capacity building is crucial, particularly in terms of training healthcare professionals and ensuring the availability of advanced artificial intelligence (AI), machine learning (ML), and laboratory equipment. Hence, this slows down the need for opting for precision medicine over traditional treatment methods.

Precision Medicine Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

15.3%

Base Year Market Size (2025)

USD 108.87 billion

Forecast Year Market Size (2035)

USD 452.07 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Precision Medicine Market Segmentation:

Technology Segment Analysis

The drug discovery technology has shown significant expansion in recent years and is expected to dominate the overall market revenue by 2035. The progress in pharmacogenomics is anticipated to provide substantial expansion in drug development for precision medicine. Pharmacogenomics aids in forecasting the effectiveness of a drug and comprehending the variations in how drugs are processed and how they interact with the body, by utilizing genetic data from individuals. Moreover, the growing focus of biopharmaceutical companies on creating precision medicine for the treatment of various diseases is anticipated to drive market expansion.

Application Segment Analysis

The oncology segment in the precision medicine market is expected to hold significant revenue share by 2035. Increasing cancer prevalence worldwide is anticipated to increase demand for precision medicine for better treatment. Precision medicine investigates the patient's genes and cancer's cause. It also helps create individualized medicine to cure patients faster than conventional ways.

For instance, a prospective clinical sequencing investigation of 10,000 patients sponsored by Memorial Sloan-Kettering Cancer Center (MSKCC) found possibly treatable genetic alterations in over 36% of advanced cancer patients. Scientists in the Department of Pathology's Molecular Diagnostics Service and the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO) developed MSK-IMPACT to repair any tumor, regardless of origin.  In Nature Communications on June 18, 2021, the MSK-ACCESS team described how the test was designed and verified. Precision oncology may improve thousands of patients' treatments with MSK-IMPACT.

End-use Segment Analysis

The hospital segment is anticipated to dominate the precision medicine market with a 55% revenue share by 2035. The growth in this segment is due to their crucial part in healthcare delivery, integrated ecosystem, improved diagnostics, and access to cutting-edge therapeutics. Hospitals customize treatment regimens based on each patient's medical history and genetics with interdisciplinary teams. These serve as hubs for innovation and customized medical care, leading to enhanced patient care and better treatment outcomes. Consequently, this drives the growth of the precision industry.

In June 2024, Janssen-Cilag International NV, a Johnson & Johnson company, announced European Commission (EC) approval for a Type II RYBREVANT (amivantamab) in combination with carboplatin and pemetrexed for initial treatment of adult patients with advanced non-small cell lung cancer and epidermal growth factor receptor 20 insertion mutations.

Our in-depth analysis of the precision medicine market includes the following segments:

          Technology
  • Bioinformatics
  • Big Data Analytics
  • Drug Discovery
  • Gene Sequencing
  • Companion Diagnostics

          Application
  • CNS, Immunology
  • Oncology
  • Respiratory

          End-use
  • Diagnostic Centers
  • Hospital
  • Healthcare IT companies
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Precision Medicine Market Regional Analysis:

North America Market Insights

North America industry is anticipated to hold largest revenue share of 45% by 2035. The region possesses a rising infrastructure of hospitals, research institutes, and diagnostic laboratories, which enables the adoption and application of precision medicine approaches. The U.S. Food and Drug Administration and Health Canada, which are regulatory bodies in North America, offer well-defined processes for the authorization and marketing of precision medicine goods and services. This, in turn, propels the development of the market in the region.

The growth of precision medicine market in the U.S. is attributed to technological developments, legislative backing, advancements in AI, increasing patient awareness, and integration with healthcare systems. Furthermore, government regulations enable the utilization of accurate diagnostic tools and targeted therapeutic approaches, ensuring that patients have access to the most advanced treatments. Therefore, the increasing adoption of personalized medicine is meant to drive market expansion.

The rising traction of precision medicine in Canada is propelled by the presence of a robust healthcare system, progress in medical therapies, and a growing number of chronic diseases.  PRiME and the Canadian Cancer Society are focused on leveraging expertise in omics, biologics, molecular chemistry, nanomedicine, liquid biopsy, and related domains to fuel innovations in precision medicine.

APAC Market Insights

By 2035, Asia Pacific precision medicine market is projected to capture over 30.5% revenue share, due to low-cost clinical trials of newly developed diagnostic products and precision medicine. Precision medicine demand is predicted to rise in developing nations like India, Japan, and China due to increased disposable income and economies. Due to research and investment in healthcare facilities and methods, the region provides various medical growth opportunities.

Precision medicine industry in India has grown due to technical advances, genetic testing accessibility, and tailored healthcare demand.  Precision medicine is predicted to develop in India due to rising disposable income, ongoing research, and the potential to improve disease treatment and prevention. Government initiatives and healthcare facilities in this country are expected to raise precision medicine demand. In January 2020, the Department of Biotechnology launched the ambitious “Genome India Project” that seeks 10,000 Indian genetic samples to create a reference genome. Given that the genome contains all genetic materials in an organism, including all DNAs, this is no small effort.

China precision medicine market is expected to rise rapidly owing to healthcare programs and investments in precision medicine. The Precision Medicine Initiative and Healthy China 2030 strategy emphasize innovation, healthcare quality, and tailored medicine to combat chronic diseases. Technological advancement, rising disease burden, rising healthcare spending, and international partnerships are thereby driving market growth in this country.

Japan's medical expenses increased to USD 276.25 billion in FY2020, accounting for 32.3% of social security payouts. This rise in medical expenses in the country increases the demand for precision medicine thus, propelling the market expansion. With the partnership announced in October 2023, NTT Life Sciences launched the Japan Precision Medicine Platform, which uses BCP systems and know-how to create a safe use environment for medical healthcare data to promote next-generation medicine research in Japan and abroad. The BCP and NTT Group seek to achieve significant healthcare structural transformation and innovation by promoting safe medical data use and improving medical care quality and efficiency. This drives precision medicine industry growth in this country.

Precision Medicine Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Precision Medicine Market Players:

    Major players in the precision medicine market are strategically advancing the field through recent approvals in RNA treatments, cell and gene therapies, and other areas. These firms are leading the way in developing specific and effective treatments, which is driving the growth of the market.

    • Novartis
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Tepnel Pharma Services
    • Qiagen
    • Menarini Silicon Biosystems
    • Eagle Genomics
    • Quest Diagnostics
    • Pfizer
    • Roche
    • Biocrates Life Sciences
    • Teva Pharmaceutical
    • NanoString Technologies

Recent Developments

  • In May 2024, Novartis announced that it had agreed to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient need.
    The deal enhances the Novartis RLT pipeline and improves the company's research infrastructure and clinical supply capabilities, aligning with Novartis' strategy focus on oncology and RLT platform innovation. The acquisition includes a strong collection of RLT programs that cover lead optimization to early development in various solid tumor indications, such as breast, prostate, and lung cancer.
  • In May 2024, QIAGEN announced the launch of its QIAseq Multimodal DNA/RNA Library Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid capture from a single sample.
  • Report ID: 6315
  • Published Date: Sep 17, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of precision medicine is assessed at USD 123.86 billion.

The global precision medicine market size surpassed USD 108.87 billion in 2025 and is projected to grow at a CAGR of more than 15.3%, reaching USD 452.07 billion revenue by 2035.

The North America precision medicine market is anticipated to capture 45% share by 2035, driven by well-defined regulatory processes and increasing adoption of personalized medicine.

Key players in the market include Tepnel Pharma Services, Qiagen, Menarini Silicon Biosystems, Eagle Genomics, Quest Diagnostics, Pfizer, Roche, Biocrates Life Sciences, Teva Pharmaceutical, NanoString Technologies.

Precision Medicine Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos